New detalimogene bladder cancer data send the minnow’s stock up 47%.
ApexOnco Front Page
Recent articles
The response rate jumps to 30% with higher doses of IMA402.
New trial starts include MediLink's 12th clinical-stage Tmalin candidate.
After trimming its cell therapy pipeline last year, the group is now out entirely.
The Titan CD8-guiding technology seems to have spawned a new variant.
The first pivotal data with raludotatug deruxtecan will feature as a late-breaker.
A Chinese phase 3 of the biparatopic DLL3 T-cell engager alveltamig will start soon.
A single-arm trial was enough for J&J’s Inlexzo nod.
